I. Angerer, M. Hecker, D. Koczan
Jan 3, 2018
Citations
1
Influential Citations
20
Citations
Quality indicators
Journal
CNS Neuroscience & Therapeutics
Abstract
Fingolimod is a sphingosine‐1‐phosphate (S1P) receptor modulator approved for the treatment of the relapsing form of multiple sclerosis (MS). It prevents the egress of lymphocyte subpopulations from lymphoid tissues into the circulation. Here, we explored the broad effects of fingolimod on gene expression in different immune cell subsets.